financetom
Business
financetom
/
Business
/
KBRA Assigns Preliminary Ratings to Greystone 2025-HC4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KBRA Assigns Preliminary Ratings to Greystone 2025-HC4
Sep 24, 2025 2:35 PM

NEW YORK--(BUSINESS WIRE)--

KBRA is pleased to announce the assignment of preliminary ratings to eight classes of Greystone 2025-HC4, a managed CRE CLO securitization with the ability to reinvest principal proceeds for 36 months including a 60-day ramp-up period to acquire one pre-identified delayed closed asset.

The transaction will initially be collateralized by 18 healthcare mortgage loans (whole loans or participations thereof) with an aggregate cutoff date in-trust balance of $433.1 million, and $18.5 million of cash collateral for the anticipated acquisition of one pre-identified asset (4.1%) which may be acquired prior to the closing date. Additionally, the transaction provides the sponsor with the ability to effectuate significant modifications to performing loans, as well as buy out defaulted and credit risk assets. All of the loans are secured by healthcare properties.

This transaction also includes an interest coverage (IC) test and a par value (overcollateralization, or OC) test. If either test is not satisfied on any determination date, on the following payment date, interest proceeds remaining after interest is paid to the Class E notes will be used to pay down the principal balances of the Class A through E notes in sequential order until the tests are satisfied, or the Class A through E notes are paid in full.

To access ratings and relevant documents, click here.

Click here to view the report.

Methodologies

CMBS: North American CMBS Multi-Borrower Rating Methodology

Structured Finance: Global Structured Finance Counterparty Methodology

CMBS: North American CMBS Property Evaluation Methodology

ESG Global Rating Methodology

Disclosures

Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above.

A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here.

Information on the meaning of each rating category can be located here.

Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com.

About KBRA

Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan’s Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S.

Doc ID: 1011417

Source: Kroll Bond Rating Agency, LLC

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SolarEdge's Q1 Results Cast Shadow With Revenue Decline, But CEO Remains Optimistic
SolarEdge's Q1 Results Cast Shadow With Revenue Decline, But CEO Remains Optimistic
May 9, 2024
SolarEdge Technologies, Inc. ( SEDG ) shares are trading lower after it reported first-quarter FY24 results. Revenues of $204.4 million, beating the consensus of $196.0 million. Revenues from the solar segment stood at $190.1 million, down 79% Y/Y, in the quarter. Adjusted gross margin was negative (6.5)% versus a positive margin of 32.6% in the prior year quarter. Adjusted operating loss stood at $(122.5)...
Update: Market Chatter: Whistleblower Claims Boeing Supplier Spirit AeroSystems Regularly Shipped Defective Fuselages
Update: Market Chatter: Whistleblower Claims Boeing Supplier Spirit AeroSystems Regularly Shipped Defective Fuselages
May 9, 2024
12:16 PM EDT, 05/09/2024 (MT Newswires) -- (Updates with Spirit AeroSystems ( SPR ) and Boeing ( BA ) comments starting from the fifth paragraph and stock move in the last paragraph.) Santiago Paredes, who worked for Spirit AeroSystems ( SPR ) , regularly found anywhere from 50 to 100, 200 defects on fuselages that were being shipped to Boeing...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
May 9, 2024
(Corrects in paragraph 6 to say Cigna and Optum are covering two or three Humira biosimilars) By Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. The drugmaker also...
Update: Converge Technology Solutions Loses 10% as Q1 Adjusted Earnings Fall
Update: Converge Technology Solutions Loses 10% as Q1 Adjusted Earnings Fall
May 9, 2024
12:16 PM EDT, 05/09/2024 (MT Newswires) -- Converge Technology Solutions ( CTSDF ) on Thursday said its first-quarter adjusted net income fell 7%. The company's adjusted earnings, excluding most one-time items, dropped to $22.7 million, or $0.11 per share, from $24.4 million, or $0.12. The net loss widened to $3.5 million from $3.4 million. Revenue slid 7.3% to $628.8 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved